Pioneering Cell Transplant Moves Us Closer to a Diabetes Cure

Breakthrough in Type 1 Diabetes Treatment

A patient diagnosed with type 1 diabetes has started producing his own insulin after receiving a transplant of genetically edited pancreatic cells. This marks a significant development, as these islet cells were modified to prevent rejection, eliminating the need for immunosuppressant medications.

Typically, type 1 diabetes occurs when the immune system mistakenly attacks islet cells in the pancreas, which are responsible for insulin production. Patients often manage the condition through strict diet and insulin injections. However, a new treatment approach focuses on replacing the damaged cells with functioning ones.

In a recent proof-of-concept study, a 42-year-old man who had been living with type 1 diabetes since he was five received islet cell transplants from a healthy donor. The cells were administered via multiple injections into his forearm muscle.

Over a 12-week period, the transplanted cells effectively produced insulin in response to glucose levels, particularly after meals. The noteworthy aspect here is that the patient did not face any need for immunosuppressants.

Normally, the immune system would identify these transplanted cells as foreign, leading to their destruction. To circumvent this, patients usually take medications that suppress their immune response. While this solution can be effective, it leaves individuals exposed to infections and other health risks.

Before the implantation, researchers made three genetic edits using the CRISPR technique. Two of these adjustments reduced the antigens that T cells use to recognize foreign elements, while the third increased the production of a protein called CD47, which helps block innate immune responses.

Interestingly, not all the genetic modifications were successful, which provided some insight into the results. Cells without effective edits were eliminated by T cells in a matter of weeks, while those with reduced antigen production were still targeted by natural killer cells and macrophages.

Only the cells that underwent all three successful genetic edits were able to survive, and fortunately, there were enough of these within the graft to remain functioning.

This technique had previously shown potential in animal tests involving monkeys and mice, but this was the first trial in humans. Past studies in human subjects have been promising but always required immunosuppressants, which come with their own set of complications.

Last year, health professionals reported that a young woman in China had received a transplant of insulin-producing cells derived from her own stem cells. In just four months, she was able to maintain adequate insulin production, keeping her blood glucose levels stable for over 98% of the day.

The researchers behind this latest study believe their method could pave the way for more effective and safer diabetes treatments, with potential applications for other cell types, thus minimizing the need for immunosuppressants in various transplants.